Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)

被引:44
作者
White, A. Clinton, Jr. [1 ]
Coyle, Christina M. [2 ]
Rajshekhar, Vedantam [3 ]
Singh, Gagandeep [4 ]
Hauser, W. Allen [5 ]
Mohanty, Aaron [1 ]
Garcia, Hector H. [6 ,7 ]
Nash, Theodore E. [8 ]
机构
[1] Univ Texas Med Branch, Galveston, TX 77555 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India
[4] Dayanand Med Coll, Ludhiana, Punjab, India
[5] Columbia Univ, New York, NY USA
[6] Inst Nacl Ciencias Neurol, Lima, Peru
[7] Univ Peruana Cayetano Heredia, Lima, Peru
[8] NIH, Bldg 10, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
Taenia solium; cysticercosis; neurocysticersosis; taeniasis; SOLITARY CYSTICERCUS GRANULOMA; LINKED IMMUNOELECTROTRANSFER BLOT; ENDOSCOPIC 3RD VENTRICULOSTOMY; TERM ANTIEPILEPTIC TREATMENT; ENHANCING CT LESION; DOUBLE-BLIND; CEREBRAL CYSTICERCOSIS; ALBENDAZOLE THERAPY; FOLLOW-UP; HYDROCEPHALUS SECONDARY;
D O I
10.1093/cid/cix1084
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Gidelines for the clinical management of patients with neurocysticercosis (NCC) were prepared by a panel of the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). The guidelines are intended for infectious disease specialists, neurologists, neurological surgeons, internists, pediatricians, and family practitioners. These guidelines present our approaches to the diagnosis and management of patients with the different forms of neurocysticercosis,including viable parenchymal neurocysticercosis,single enhancing lesions, calcified parenchymal neurocysticercosis,ventricular neurocysticercosis, and subarachnoid neurocysticercosis. Our recommendations are based on the best evidence available. Due to the complex variations in clinical manifestations and the limitations of the literature, many of the recommendations are based on observational studies, anecdotal data, or expert opinion rather than randomized clinical trials. The approaches we describe are intended to be both applicable and feasible in the United States and Canada (for simplicity, referred to here as North America). The recommendations may not apply for settings where resource constraints may limit their applicability. The executive summary below lists the recommendations for the diagnosis and clinical management of neurocysticercosis. A detailed description of the methods, background, and evidence summaries that support each of the recommendations can be found online in the full text of the guidelines. A criterion for grading evidence is presented in Figure 1 [1]. Note that diagnosis and management of patients with neurocysticercosis can be challenging even with expert guidelines. Due to this complexity, clinicians with little experience with this disease should have a low threshold for consultation with an expert in the disease. © The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.
引用
收藏
页码:E49 / E75
页数:27
相关论文
共 152 条
[1]   Focal limb dystonia in a patient with a cerebellar mass [J].
Alarcón, F ;
Tolosa, E ;
Muñoz, E .
ARCHIVES OF NEUROLOGY, 2001, 58 (07) :1125-1127
[2]   CEREBRAL CYSTICERCOSIS AS A RISK FACTOR FOR STROKE IN YOUNG AND MIDDLE-AGED PEOPLE [J].
ALARCON, F ;
VANORMELINGEN, K ;
MONCAYO, J ;
VINAN, I .
STROKE, 1992, 23 (11) :1563-1565
[3]   CEREBRAL CYSTICERCOSIS AND STROKE [J].
ALARCON, F ;
HIDALGO, F ;
MONCAYO, J ;
VINAN, I ;
DUENAS, G .
STROKE, 1992, 23 (02) :224-228
[4]  
Albenza (albendazole), PROD INF
[5]  
[Anonymous], 2000, MMWR Recomm Rep, V49, P1
[6]   Concurrent asymptomatic inflammatory aneurysm and ischemic stroke due to cysticercal arteritis [J].
Arauz, Antonio ;
Ruiz-Navarro, Francisco ;
Silos, Humberto ;
Camilo Vargas-Gonzalez, Juan ;
Arguelles-Morales, Nayelli ;
Reyes, Marisela ;
Ruiz-Franco, Angelica ;
Rivera, Aleyda ;
Fleury, Agnes .
CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 (12) :2540-2542
[7]   Evidence-based guideline: Treatment of parenchymal neurocysticercosis Report of the Guideline Development Subcommittee of the American Academy of Neurology [J].
Baird, Ruth Ann ;
Wiebe, Sam ;
Zunt, Joseph R. ;
Halperin, John J. ;
Gronseth, Gary ;
Roos, Karen L. .
NEUROLOGY, 2013, 80 (15) :1424-1429
[8]   EXTRAPARENCHYMAL NEUROCYSTICERCOSIS - REPORT OF 5 CASES AND REVIEW OF MANAGEMENT [J].
BANDRES, JC ;
WHITE, AC ;
SAMO, T ;
MURPHY, EC ;
HARRIS, RL .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (05) :799-811
[9]   Large cerebral infarction during praziquantel therapy in neurocysticercosis [J].
Bang, OY ;
Heo, JH ;
Choi, SA ;
Kim, DI .
STROKE, 1997, 28 (01) :211-213
[10]   Frequency of cerebral arteritis in subarachnoid cysticercosis -: An angiographic study [J].
Barinagarrementeria, F ;
Cantú, C .
STROKE, 1998, 29 (01) :123-125